Ravi Gupta and colleagues argue that we need to reconsider standards for targeted pharmaceutical marketing to doctors through speaker programmes, consulting programmes, and advisory board positions
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: